Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
61755-0054-01 61755-0054 Linvoseltamab-gcpt LYNOZYFIC 5.0 mg/2.5mL Immunotherapy Monoclonal Antibody BCMA, CD3 Intravenous Jul 2, 2025 In Use
57894-0449-01 57894-0449 Teclistamab-cqyv TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
55513-0954-21 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 1, 2025 In Use
71837-1000-02 71837-1000 Zenocutuzumab BIZENGRI 20.0 mg/mL Immunotherapy Monoclonal Antibody HER2, HER3 Intravenous Dec 16, 2024 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst, Trastuzumab OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
65219-0672-01 65219-0672 Denosumab BOMYNTRA 70.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jun 30, 2025 In Use
50242-0132-01 50242-0132 Trastuzumab Herceptin 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Feb 10, 2017 In Use
70121-1755-01 70121-1755 bevacizumab-maly ALYMSYS 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 Oct 31, 2028 In Use
50242-0051-21 50242-0051 Rituximab Rituxan 10.0 mg/mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 26, 1997 In Use
61314-0228-94 61314-0228 Denosumab WYOST 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jun 2, 2025 In Use
67457-0991-15 67457-0991 Trastuzumab OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov 29, 2019 Feb 28, 2027 In Use
63459-0303-43 63459-0303 TRASTUZUMAB HERZUMA 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Mar 16, 2020 In Use
00173-0808-02 00173-0808 Ofatumumab Arzerra Immunotherapy Monoclonal Antibody CD20 Oct 26, 2009 Mar 31, 2012 No Longer Used
55513-0224-21 55513-0224 Rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jul 21, 2025 In Use
83257-0009-11 83257-0009 Bevacizumab-nwgd JOBEVNE 25.0 mg/mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 10, 2025 In Use
50633-0230-01 50633-0230 Naxitamab DANYELZA 40.0 mg/10mL Immunotherapy Monoclonal Antibody GD2 Intravenous Sep 1, 2026 In Use
57894-0514-01 57894-0514 AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT) RYBREVANT FASPRO 2240.0 mg/14mL, 28000.0 mg/14mL Immunotherapy Monoclonal Antibody EGFR, MET Subcutaneous Dec 19, 2025 In Use
70121-2702-01 70121-2702 Denosumab-mobz Boncresa 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Dec 23, 2025 In Use
65219-0670-01 65219-0670 Denosumab BOMYNTRA 70.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jun 30, 2025 In Use
72606-0038-01 72606-0038 Denosumab-bmwo Osenvelt 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 2, 2025 In Use
55513-0132-21 55513-0132 trastuzumab-anns Kanjinti 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Jul 1, 2025 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
00143-9165-01 00143-9165 Denosumab-qbde ENOBY 60.0 mg/mL Ancillary Therapy Monoclonal Antibody RANKL Subcutaneous Jan 8, 2026 In Use
69448-0021-63 69448-0021 Denosumab-desu OSVYRTI 60.0 mg/mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Jul 6, 2026 In Use
73535-0208-01 73535-0208 Tafasitamab-cxix MONJUVI 200.0 mg/5mL Immunotherapy Monoclonal Antibody CD19 Intravenous Aug 5, 2020 Nov 30, 2025 No Longer Used

Found 12611 results — Export these results